Nexalin Technology

Nexalin Technology LT Debt/Equity

The Long-Term Debt to Equity Ratio of Nexalin Technology (NXL) as of Nov 11, 2026 is -0.01. In the previous year, Long-Term Debt to Equity Ratio was -0.03 — a change of -58.57% (higher).

LT Debt/Equity

-0.01

YoY

-58.57%

Last updated:

Long-Term Debt to Equity Ratio of Nexalin Technology is 2021 -0.01 . Long-Term Debt to Equity Ratio of Nexalin Technology was 2020 -0.03 . It decreases by -58.57% higher compared to the previous year.

The Nexalin Technology LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2020
-0.03 USD
Jan 1, 2021
-0.01 USD
The Nexalin Technology LT Debt/Equity history
YEARLT Debt/EquityYoY
-0.01-58.57%
-0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Long-Term Debt to Equity Ratio of Nexalin Technology is -0.01 in 2021.

Long-Term Debt to Equity Ratio of Nexalin Technology changed from -0.03 to -0.01, representing a -58.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Nexalin Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Nexalin Technology

All Key Metrics — Nexalin Technology